Skip to content
Education
Isle of NAM
Gene Editing

Gene Editing

Table of Contents

Definition

Gene editing (e.g., CRISPR) refers to the repurposing of a prokaryotic adaptive immune mechanism for the deliberate and sequence-specific modification of genomic DNA in living cells. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) loci, together with their associated Cas genes, constitute a heritable record of previous encounters with bacteriophages and plasmids: short spacer sequences captured from invasive genetic elements are transcribed into CRISPR RNA, which then guides Cas nucleases to cleave matching DNA upon reinfection1. Jinek and colleagues demonstrated in 2012 that the Cas9 endonuclease could be programmed with a single guide RNA (sgRNA), a synthetic fusion of the native CRISPR RNA and trans-activating CRISPR RNA, to cleave virtually any DNA sequence positioned adjacent to a short protospacer-adjacent motif (PAM)2.

Structurally, Cas9 is a bilobed enzyme in which the HNH domain cleaves the target strand and the RuvC domain cleaves the non-target strand, producing a double-strand break approximately three base pairs upstream of the PAM; crystal structures of Cas9 in complex with guide RNA and target DNA defined this bilobed architecture and the structural basis for guide-dependent target recognition3. The resulting double-strand break is resolved by the host cell through non-homologous end joining, which introduces insertions or deletions that can disrupt gene function, or through homology-directed repair, which can copy a supplied donor template into the locus for precise sequence replacement4.

Purpose

The primary value proposition of CRISPR lies in its programmability: because target specificity is conferred by a short RNA spacer rather than by laborious protein engineering, a change of approximately twenty nucleotides in the sgRNA is sufficient to redirect the nuclease to a new genomic locus5. This design simplicity, together with low cost and the capacity for multiplexed editing of several loci simultaneously, is the basis on which CRISPR supplanted the preceding engineered-nuclease platforms, namely zinc-finger nucleases and transcription activator-like effector nucleases, which required the re-engineering of a novel protein for each target6.

Human relevance is central to the platform. Editing was demonstrated in human cells within months of the original programmable-nuclease reports5 7, and the technology now supports the direct study and correction of human disease genetics in patient-derived cells rather than solely in animal surrogates. This human relevance has culminated in regulatory approvals: on December 8, 2023, the United States Food and Drug Administration approved Casgevy, the first authorized therapy to utilize CRISPR/Cas9 genome editing, for sickle cell disease in patients twelve years of age and older with recurrent vaso-occlusive crises8. In addition, catalytically inactive Cas9 permits reversible and sequence-specific transcriptional control of human genes, providing a durable alternative to legacy knockdown technologies such as RNA interference, which suffer from incomplete and off-target depletion9.

Methodology

Construction of a CRISPR editing experiment proceeds from guide RNA design through delivery, editing, and validation. Guide RNAs are selected to maximize predicted on-target activity while minimizing predicted off-target activity, using design algorithms trained on large empirical datasets10, and are commonly evaluated in web tools such as CRISPOR, which integrates multiple on-target and off-target scoring algorithms and genome-annotated specificity checks11.

Key components and protocols include the following:

  • Guide RNA expression: a twenty-nucleotide spacer sequence is cloned downstream of a U6 promoter or synthesized as a CRISPR RNA together with the trans-activating CRISPR RNA, following the configuration established in the original human-cell demonstrations5.
  • Effector delivery: Cas9 is delivered as a plasmid, as messenger RNA, or as a pre-formed ribonucleoprotein complex by transfection or electroporation; for in vivo administration, lipid nanoparticles encapsulating Cas9 messenger RNA and guide RNA have been validated in patients12.
  • Substrates: cultured cell lines, induced pluripotent stem cells, organoids, zygotes, and primary hematopoietic stem and progenitor cells, the last of which form the substrate of the approved ex vivo therapy13.
  • Outcome control: for gene disruption, non-homologous end joining is permitted to generate frameshift indels; for precise replacement, a single-stranded donor oligonucleotide or longer homologous template is supplied so that homology-directed repair copies the desired sequence into the locus4.
  • Validation: editing efficiency is confirmed by amplicon sequencing, and unbiased genome-wide off-target activity is profiled by assays such as GUIDE-seq, which captures double-strand breaks across the genome rather than only at computationally predicted sites14.

Performance

Empirical performance in the clinic is substantial. In the phase 3 trial of exagamglogene autotemcel for severe sickle cell disease, 44 patients received edited CD34-positive hematopoietic stem and progenitor cells with a median follow-up of 19.3 months; of the 30 evaluable patients, 29 (97 percent) were free of severe vaso-occlusive crises for at least twelve consecutive months, and all 30 were free of hospitalization for such crises13. For in vivo editing, a single intravenous infusion of a lipid nanoparticle formulation at 0.3 mg per kilogram produced a mean 87 percent reduction in serum transthyretin at day 28, with only mild adverse events12.

Reproducibility across laboratories is supported by standardized design algorithms and validation tools10 11, yet several technical boundaries remain. Specificity is guide- and locus-dependent, and unbiased assays reveal off-target cleavage sites that computational prediction fails to identify14. Double-strand break repair can also produce large deletions and complex rearrangements extending far from the cut site, with attendant risk of functional consequences15. Homology-directed repair is inefficient compared with non-homologous end joining and is constrained to cell-cycle stages permissive of repair4. Targeting remains restricted by the PAM requirement of each nuclease6. Finally, the approved ex vivo therapy requires myeloablative conditioning prior to infusion, which imposes a substantial treatment burden8.

Applications

Primary research applications include functional genomics and disease modeling. Genome-scale CRISPR-Cas9 knockout screening enables systematic interrogation of gene function in human cells and has become a standard method for identifying genes involved in specific biological pathways16. Repurposed catalytically inactive Cas9 likewise enables gene repression and activation for the study of gene regulation without altering the underlying sequence9.

Clinical and industrial applications have reached several distinct deployment stages:

  • Therapeutics, approved and deployed: Casgevy is approved for sickle cell disease in patients twelve years and older with recurrent vaso-occlusive crises8 and for transfusion-dependent beta-thalassemia in the same age group17.
  • Therapeutics, in vivo investigational: lipid nanoparticle delivery of Cas9 to the liver is in clinical development for transthyretin amyloidosis and demonstrates the feasibility of intravenous genome editing12.
  • Diagnostics, field-deployed: Cas12-based assays provide rapid molecular detection of pathogens, including SARS-CoV-2 in respiratory samples18.
  • Agriculture, entering regulated markets: CRISPR-based editing is applied to staple crops for improved resilience, yield, and nutritional value, with base and prime editing broadening the scope of feasible traits19.

The core editing workflow is mature and standardized in research settings; therapeutic deployment is at its earliest stage, with the first approved products confined to hematologic indications; diagnostics have been field-deployed at scale; and agricultural products are progressing through regulatory frameworks8 17 18 19.

Variations

  • CRISPR-Cas9 — The foundational RNA-guided DNA endonuclease platform, programmed by a single guide RNA to introduce double-strand breaks for knockout or homology-directed replacement, and the effector underlying the first approved genome-editing therapies2 5 8.
  • Base Editing — Fusion of a catalytically inactive Cas9 to a deaminase enzyme to chemically convert single bases without double-strand cleavage; cytosine base editors convert C to T20, while adenine base editors convert A to G with high efficiency and precision21.
  • Prime Editing — A Cas9 nickase fused to a reverse transcriptase, programmed by an engineered guide RNA to write new sequences into genomic DNA through search-and-replace editing that requires neither double-strand breaks nor donor DNA templates22.
  • CRISPR-Cas12a — A Class 2 effector, originally designated Cpf1, that recognizes a thymine-rich PAM, cuts DNA with staggered ends, and requires a single CRISPR RNA rather than a dual-RNA guide23.
  • CRISPR-Cas13 — A single-component, RNA-guided RNA-targeting effector, originally designated C2c2, that degrades RNA transcripts directly and underpins nucleic-acid detection platforms24.
  • CRISPR Interference and Activation — Catalytically inactive Cas9 deployed as a programmable platform for sequence-specific repression and activation of gene expression, offering reversible and titratable transcriptional control9.

  1. Barrangou, R., et al., CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes, Science, March 23, 2007.
    This foundational study demonstrated that Streptococcus thermophilus integrates short DNA sequences from infecting bacteriophes into its CRISPR loci and that these spacer sequences confer sequence-specific resistance to subsequent viral infection, thereby establishing CRISPR as an adaptive immune system in prokaryotes. ↩︎

  2. Jinek, M., et al., A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity, Science, August 17, 2012.
    The authors showed that Cas9 can be programmed with a synthetic single-guide RNA, fusing the native CRISPR RNA and trans-activating CRISPR RNA, to cleave any DNA sequence adjacent to an appropriate protospacer-adjacent motif, establishing the programmable nuclease that underpins modern genome editing. ↩︎ ↩︎

  3. Nishimasu, H., et al., Crystal Structure of Cas9 in Complex with Guide RNA and Target DNA, Cell, February 2014.
    This structural study presented the crystal structure of Cas9 bound to a guide RNA and its target DNA, revealing the bilobed architecture of the nuclease, the placement of the HNH and RuvC nuclease domains, and the conformational basis for guide-dependent recognition of target DNA. ↩︎

  4. Hsu, P.D., Lander, E.S., and Zhang, F., Development and Applications of CRISPR-Cas9 for Genome Engineering, Cell, June 2014.
    This review synthesized the state of the platform shortly after its introduction to human cells, describing the mechanics of guide RNA design, protospacer-adjacent motif requirements, and the competing repair pathways of non-homologous end joining and homology-directed repair that determine editing outcomes. ↩︎ ↩︎ ↩︎

  5. Cong, L., et al., Multiplex Genome Engineering Using CRISPR/Cas Systems, Science, February 15, 2013.
    This study demonstrated that Cas9 guided by short synthetic RNAs could modify endogenous genomic loci in human cells through both non-homologous end joining and homology-directed repair, and that multiple loci could be edited simultaneously with a single nuclease, establishing multiplexed editing in mammalian genomes. ↩︎ ↩︎ ↩︎ ↩︎

  6. Doudna, J.A., and Charpentier, E., The New Frontier of Genome Engineering with CRISPR-Cas9, Science, November 28, 2014.
    This review by the platform co-discoverers recounts the origins of CRISPR biology and explains why RNA-guided targeting displaced earlier engineered-nuclease technologies, highlighting the simplicity of retargeting by guide RNA design rather than protein engineering. ↩︎ ↩︎

  7. Mali, P., et al., RNA-Guided Human Genome Engineering via Cas9, Science, February 15, 2013.
    This companion demonstration, published alongside Cong and colleagues, showed that Cas9 together with short guide RNAs could be directed to endogenous human loci, providing one of the two first validations of programmable genome editing in human cells. ↩︎

  8. U.S. Food and Drug Administration, FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease, FDA Press Announcement, December 8, 2023.
    This announcement records the approval of Casgevy as the first FDA-authorized therapy to employ CRISPR/Cas9 genome editing, indicated for sickle cell disease in patients twelve years and older with recurrent vaso-occlusive crises, following autologous stem cell editing and myeloablative conditioning. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎

  9. Qi, L.S., et al., Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression, Cell, February 2013.
    This study showed that a catalytically inactive Cas9, guided by a short RNA, can occupy promoter sequences and block transcription without cutting DNA, establishing CRISPR interference and CRISPR activation as programmable and reversible alternatives to RNA interference for controlling gene expression. ↩︎ ↩︎ ↩︎

  10. Doench, J.G., et al., Optimized sgRNA Design to Maximize Activity and Minimize Off-Target Effects of CRISPR-Cas9, Nature Biotechnology, January 18, 2016.
    Using large-scale empirical activity datasets, the authors derived sgRNA design rules and scoring algorithms that improve editing efficiency and reduce off-target cleavage, providing a quantitative basis for guide RNA selection that remains widely embedded in design tools. ↩︎ ↩︎

  11. Haeussler, M., et al., Evaluation of Off-Target and On-Target Scoring Algorithms and Integration into the Guide RNA Selection Tool CRISPOR, Genome Biology, July 5, 2016.
    This work evaluated the principal on-target and off-target scoring algorithms against experimental data and integrated them into CRISPOR, a widely used web tool that annotates candidate guide RNAs with specificity and efficiency predictions for a broad range of genomes. ↩︎ ↩︎

  12. Gillmore, J.D., et al., CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis, New England Journal of Medicine, August 5, 2021.
    This first-in-human study of in vivo genome editing demonstrated that a single intravenous infusion of lipid nanoparticles encapsulating Cas9 messenger RNA and a transthyretin guide RNA reduced serum transthyretin by a mean of 52 percent at 0.1 mg per kilogram and 87 percent at 0.3 mg per kilogram at day 28, with only mild adverse events. ↩︎ ↩︎ ↩︎

  13. Frangoul, H., et al., Exagamglogene Autotemcel for Severe Sickle Cell Disease, New England Journal of Medicine, May 9, 2024.
    This phase 3 study of the approved CRISPR therapy reported that, among 30 evaluable patients treated with edited CD34-positive cells, 29 achieved freedom from severe vaso-occlusive crises for at least twelve consecutive months and all 30 achieved freedom from related hospitalization, with a median follow-up of 19.3 months across 44 treated patients. ↩︎ ↩︎

  14. Tsai, S.Q., et al., GUIDE-seq Enables Genome-Wide Profiling of Off-Target Cleavage by CRISPR-Cas Nucleases, Nature Biotechnology, December 16, 2014.
    This study introduced GUIDE-seq, an unbiased genome-wide assay that tags double-strand breaks with sequencing barcodes, and demonstrated that cleavage occurs at numerous off-target sites that sequence-alignment-based prediction does not identify, establishing a standard method for nuclease specificity assessment. ↩︎ ↩︎

  15. Kosicki, M., et al., Repair of Double-Strand Breaks Induced by CRISPR-Cas9 Leads to Large Deletions and Complex Rearrangements, Nature Biotechnology, July 16, 2018.
    This study showed that repair of Cas9-induced double-strand breaks frequently produces large deletions and complex genomic rearrangements extending many kilobases from the target site, observations that can escape standard short-read genotyping and that inform current biosafety evaluation of editing outcomes. ↩︎

  16. Shalem, O., et al., Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells, Science, January 3, 2014.
    This study established genome-wide CRISPR-Cas9 knockout screening by delivering a lentiviral single-guide RNA library across the human genome, demonstrating both negative-selection and positive-selection screening formats and establishing a general method for assigning gene function in human cells. ↩︎

  17. U.S. Food and Drug Administration, FDA Roundup: January 16, 2024, FDA Press Announcement, January 16, 2024.
    This announcement records the approval of Casgevy for transfusion-dependent beta-thalassemia in patients twelve years of age and older, extending the indication of the first CRISPR/Cas9-based therapy beyond sickle cell disease. ↩︎ ↩︎

  18. Broughton, J.P., et al., CRISPR-Cas12-Based Detection of SARS-CoV-2, Nature Biotechnology, April 16, 2020.
    This study described DETECTR, an isothermal Cas12-based assay that detects SARS-CoV-2 RNA from respiratory specimens with near-single-molecule sensitivity in approximately thirty minutes, demonstrating the deployment of CRISPR effectors as field-ready molecular diagnostics. ↩︎ ↩︎

  19. Chen, F., et al., Recent Advances of CRISPR-Based Genome Editing for Enhancing Staple Crops, Frontiers in Plant Science, September 23, 2024.
    This open-access review surveys CRISPR applications in staple crops such as rice and maize, covering improvements in yield, stress tolerance, and nutritional value, and emphasizing how base editing, prime editing, and novel Cas effectors broaden the accessible range of agricultural traits. ↩︎ ↩︎

  20. Komor, A.C., et al., Programmable Editing of a Target Base in Genomic DNA Without Double-Stranded DNA Cleavage, Nature, April 20, 2016.
    This study introduced cytosine base editing by fusing a deaminase enzyme to catalytically inactive Cas9, enabling direct conversion of cytosine to thymine at a targeted genomic position without generating a double-strand break, thereby avoiding much of the indel and rearrangement risk of nuclease editing. ↩︎

  21. Gaudelli, N.M., et al., Programmable Base Editing of A-T to G-C in Genomic DNA Without DNA Cleavage, Nature, November 2017.
    This study reported the development of adenine base editors through directed evolution of a transfer RNA adenosine deaminase, enabling efficient and precise conversion of adenine to guanine in genomic DNA without cleavage, and demonstrating correction of pathogenic mutations in human cells. ↩︎

  22. Anzalone, A.V., et al., Search-and-Replace Genome Editing Without Double-Strand Breaks or Donor DNA, Nature, October 21, 2019.
    This study introduced prime editing, comprising a Cas9 nickase fused to an engineered reverse transcriptase and programmed by an extended guide RNA, which installs specified sequence changes including all possible base conversions, insertions, and deletions without double-strand breaks or exogenous donor templates. ↩︎

  23. Zetsche, B., et al., Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System, Cell, October 2015.
    This study characterized Cas12a, originally designated Cpf1, as a Class 2 effector that requires only a single CRISPR RNA, recognizes a thymine-rich protospacer-adjacent motif, and generates staggered double-strand cuts, properties that expanded the targetable sequence space and simplified multiplexed editing. ↩︎

  24. Abudayyeh, O.O., et al., C2c2 Is a Single-Component Programmable RNA-Guided RNA-Targeting CRISPR Effector, Science, August 5, 2016.
    This study characterized Cas13, originally designated C2c2, as a nuclease that targets RNA rather than DNA using a single guide RNA, with collateral ribonuclease activity upon target recognition, a property that later enabled rapid nucleic-acid detection platforms. ↩︎